Novo Nordisk’s ziltivekimab just failed the test that mattered. The IL-6 inhibitor missed its primary endpoint in the ZEUS Phase 3 trial, posting a hazard ratio of 0.99 against placebo for reducing heart attack, stroke and cardiovascular death in more than 6,300 patients with atherosclerotic disease, chronic kidney disease and inflammation. Novo shares dropped nearly 9% to $47.10 Friday morning.
Ziltivekimab hit its biomarker targets, cutting C-reactive protein as designed. That reduction in inflammation never translated into fewer cardiovascular events, the exact disconnect between mechanism and outcome that sinks cardiometabolic programs. “Although ziltivekimab produced the expected biological effect, this did not result in MACE benefits in this population,” Novo CSO Martin Holst Lange said in the release.
Novo bought this asset in 2020, paying $725 million upfront for Corvidia Therapeutics, with up to $2.1 billion tied to milestones ziltivekimab now won’t hit on this trial. Two more cardiovascular outcomes studies, HERMES and ARTEMIS, are still running and expected to read out in the first half of 2027.
The failure didn’t stay contained to Novo. Shares of BioAge, a smaller biotech chasing the same inflammation-driven cardiovascular hypothesis with an NLRP3 inhibitor, fell more than 50% Friday morning. That’s the read-across risk: one Phase 3 miss can reprice an entire mechanistic thesis across a sector, not just the company that ran the trial.
Novo reports second-quarter earnings next week. Investors will be watching oral Wegovy, not ziltivekimab.
— Sarah Chen